Angion Biomedica Corp.

47 articles with Angion Biomedica Corp.

• Angion Biomedica Corp. To Present Clinical And Preclinical Data At The Upcoming American Society of Nephrology Conference In San Diego

  11/2/2015

• Angion Biomedica Corp. To Commence Phase 2 Clinical Trial Of BB3 In Acute Kidney Injury

  6/9/2015

• Angion Biomedica Corp. Advances BB3 Into Pivotal Phase 3 Clinical Trial In Renal Transplant Patients With Delayed Graft Function

  5/14/2015

• Organ Recovery Biotech Angion Biomedica Corp. Files For A $35 Million IPO

  4/15/2014

• First Patient Treated in Angion Biomedica Corp.'s Phase II BB3 Heart Attack Clinical Trial

  7/19/2012

• Angion Biomedica Corp. Receives Fast Track and Orphan Drug Product Designations from FDA for its Lead Therapeutic, BB3

  7/6/2010

• Angion Biomedica Corp. Has Signed Licensing Option With Memorial Sloan-Kettering Cancer Center For Novel Vaccine Platform

  1/8/2009